• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Vaxcyte, Inc. - Common Stock (NQ:PCVX)

    45.84 -0.21 (-0.46%)
    Streaming Delayed Price Updated: 4:00 PM EST, Jan 12, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 642,890
    Open 46.17
    Bid (Size) 45.82 (1,300)
    Ask (Size) 45.86 (500)
    Prev. Close 46.05
    Today's Range 44.57 - 46.17
    52wk Range 27.66 - 93.77
    Shares Outstanding 93,706,790
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Vaxcyte's Chief Technical Ops Officer Sells Shares ↗
    Focused on next-generation vaccines for bacterial diseases, this biotech just reported a notable insider sale amid a challenging year. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Vaxcyte Doses First Participants in the OPUS Phase 3, Noninferiority Trial Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults
    From Vaxcyte, Inc.
    Via GlobeNewswire

    Performance

    YTD
    -1.4%
    -1.4%
    1 Month
    +3.0%
    +3.0%
    3 Month
    +4.6%
    +4.6%
    6 Month
    +26.0%
    +26.0%
    1 Year
    -43.5%
    -43.5%

    More News

    Read More
    News headline image
    These 3 Stocks Are Using Buybacks to Signal Market Confidence ↗
    Via MarketBeat
    News headline image
    Vaxcyte Reports Third Quarter 2025 Financial Results and Provides Business Update Including Final Data from Positive VAX-24 Infant Phase 2 Dose-Finding Study
    From Vaxcyte, Inc.
    Via GlobeNewswire
    News headline image
    Thermo Fisher Launches Four-Part Bond Offering Ahead Of Possible Government Shutdown ↗
    Via Benzinga
    Topics Bonds
    News headline image
    Vaxcyte to Establish Fill-Finish Manufacturing in North Carolina as Key Element of Long-Term United States Commercial Supply Strategy Representing Up to $1 Billion in Manufacturing and Services
    From Vaxcyte, Inc.
    Via GlobeNewswire
    News headline image
    Merck Advances Childhood Pneumococcal Care With Promising Vaccine Data ↗
    Via Benzinga
    News headline image
    Vaxcyte Advances VAX-31 Infant Phase 2 Dose-Finding Study with First Participants Receiving VAX-31 Optimized Dose
    From Vaxcyte, Inc.
    Via GlobeNewswire
    News headline image
    Redwire Posts Downbeat Q2 Results, Joins Tandem Diabetes Care, Fortinet, Symbotic And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    Vaxcyte (PCVX) Q2 Loss Widens 11% ↗
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    Vaxcyte Reports Second Quarter 2025 Financial Results and Provides Business Update, Highlighting Key Clinical and Regulatory Progress for VAX-31, a Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV)
    From Vaxcyte, Inc.
    Via GlobeNewswire
    News headline image
    Vaxcyte Reports First Quarter 2025 Financial Results and Provides Business Update
    From Vaxcyte, Inc.
    Via GlobeNewswire
    News headline image
    Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors
    From Vaxcyte, Inc.
    Via GlobeNewswire
    News headline image
    Ulta Beauty To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
    Via Benzinga
    News headline image
    Top stock movements in today's session. ↗
    Via Chartmill
    News headline image
    Monday's session: top gainers and losers ↗
    Via Chartmill
    News headline image
    12 Health Care Stocks Moving In Monday's Intraday Session ↗
    Via Benzinga
    News headline image
    These stocks are gapping in today's session ↗
    Via Chartmill
    News headline image
    Dow Gains Over 100 Points; NewGenIvf Group Shares Plummet ↗
    Via Benzinga
    Topics Stocks
    News headline image
    Monday's pre-market session: top gainers and losers ↗
    Via Chartmill
    News headline image
    Nasdaq Tumbles Over 300 Points; Chicago PMI Rises In March ↗
    Via Benzinga
    News headline image
    Moderna, Vaxcyte, Novavax Hammered After Key FDA Official Peter Marks Resigns ↗
    Via Investor's Business Daily
    News headline image
    Vaxcyte Plans To Drop Developing One Pneumococcal Conjugate Vaccine ↗
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    Vaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding Study
    From Vaxcyte, Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is Vaxcyte, Inc. - Common Stock publicly traded?
    Yes, Vaxcyte, Inc. - Common Stock is publicly traded.
    What exchange does Vaxcyte, Inc. - Common Stock trade on?
    Vaxcyte, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Vaxcyte, Inc. - Common Stock?
    The ticker symbol for Vaxcyte, Inc. - Common Stock is PCVX on the Nasdaq Stock Market
    What is the current price of Vaxcyte, Inc. - Common Stock?
    The current price of Vaxcyte, Inc. - Common Stock is 45.84
    When was Vaxcyte, Inc. - Common Stock last traded?
    The last trade of Vaxcyte, Inc. - Common Stock was at 01/12/26 04:00 PM ET
    What is the market capitalization of Vaxcyte, Inc. - Common Stock?
    The market capitalization of Vaxcyte, Inc. - Common Stock is 4.30B
    How many shares of Vaxcyte, Inc. - Common Stock are outstanding?
    Vaxcyte, Inc. - Common Stock has 4B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.